• FDA OKs Bispecific Antibody for Rare Lung Cancer Subtype

    27 days ago - By MedPageToday

    The FDA approved amivantamab-vmjw on Friday as the first treatment for patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
    Amivantamab is a bispecific antibody that targets...
    Read more ...

     

  • FDA approves Rybrevant for treating subset of non-small cell lung cancer

    FDA approves Rybrevant for treating subset of non-small cell lung cancer

    27 days ago - By News Medical

    Today, the U.S. Food and Drug Administration approved Rybrevant as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor exon 20 insertion mutations.
    Read more ...

     

  • FDA OKs First Targeted Therapy for Subset of Patients With NSCLC

    27 days ago - By Medscape

    There is now a specific treatment for patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations - amivantamab .
    Medscape Medical News
    Read more ...

     

  • FDA approves Rybrevant for NSCLC with EGFR exon 20 insertion mutations

    FDA approves Rybrevant for NSCLC with EGFR exon 20 insertion mutations

    28 days ago - By Healio

    The FDA approved amivantamab-vmjw for treatment of adults with non-small cell lung cancer who harbor EGFR exon 20 insertion mutations.
    Amivantamab-vmjw is an EGFR and mesenchymal epithelial transition factor bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.
    The FDA also approved Guardant360 CDx as a companion diagnostic for amivantamab-vmjw.
    “Advances in precision oncology continue to facilitate drug development, allowing diseases like lung cancer to be subset into biomarker-defined
    Read more ...